WORKING GROUP 2. DILI RISK STRATIFICATION
Deputy for Leader WG2 (michael.merz@t-online.de)
University Hospital Zurich (Switzerland)
- Clinical Pharmacologist and Drug Safety Expert
- 1993-1998: Quintiles Research, Freiburg, Germany
- 1998-2017: Novartis Pharma AG, Basel, Switzerland
- Head Modeling and Simulation, Clinical Pharmacology
- Global Safety Profiling Director, Exploratory Clinical Development
- Section Head Systems Toxicology & Head Safety Networks, Translational Sciences
- Chair investigative Liver Expert Team, Novartis Institutes for BioMedical Research
- 2010-2016: Project coordinator IMI SAFE-T consortium for clinical safety biomarker qualification
- Since 05/2017: Independent consultant, focus on Drug-Induced Liver Injury; Consortium Coordinator at University Hospital Zürich, Switzerland
- In charge of proposal H2020-JTI-IMI2-2017-13-two-stage: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease